This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Original article
Adusumilli, P. S. et al. A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab. Cancer Discov. https://doi.org/10.1158/2159-8290.CD-21-0407 (2021)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Killock, D. CAR T cells show promise in mesothelioma. Nat Rev Clin Oncol 18, 541 (2021). https://doi.org/10.1038/s41571-021-00547-4
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-021-00547-4